Rimon Advises Unleash Immuno Oncolytics in Licensing Agreement with TransCode Therapeutics

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage company pioneering immuno-oncology and RNA for the treatment of high-risk and advanced cancer, announced that it has entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc. (“Unleash”). Unleash will receive a one-time payment of 1,136,364 shares of a new series of non-voting convertible preferred stock of TransCode, convertible into an equal number of shares of common stock of TransCode (the “Preferred Stock”).  The Preferred Stock represents 6.8% of TransCode’s common stock on a fully diluted basis, assuming conversion of all TransCode preferred stock outstanding.

Rimon Partner, David Case represented Unleash on the licensing aspect of the transaction.

We congratulate Unleash on this milestone!

Read more here.